肠促胰岛素可预测EDEN试验中肠内营养策略的应答:一项二次分析
EDEN试验二次分析,纳入889例ARDS患者(滋养性肠内营养452例,全量肠内营养437例),检测干预前血浆GIP、GLP-1及宿主免疫应答生物标志物。以60天死亡率为主要终点,在校正人口学、疾病严重程度、糖尿病及IL-6后检验治疗与肠促胰岛素的交互作用。结果GIP可预测肠内营养策略的异质性治疗效应(校正交互p=0.01),最高GIP三分位者滋养性喂养死亡率低于全量喂养(14.1% vs 27.2%),其他三分位死亡率相似;GLP-1、ARDS亚表型及基线死亡风险未预测异质性治疗效应。GIP可能作为指导ARDS肠内营养强度的生物标志物,尚需验证。
要点
- ARDS患者中,最高GIP三分位者接受滋养性肠内营养较全量肠内营养60天死亡率更低(14.1% vs 27.2%),其他GIP三分位无此差异。
- GIP预测肠内营养策略的异质性治疗效应,校正交互p=0.01(校正人口学、疾病严重程度、糖尿病及IL-6)。
- GLP-1、ARDS亚表型及基线死亡风险均未预测肠内营养策略的异质性治疗效应。
- 该分析为EDEN试验二次分析,GIP作为指导ARDS肠内营养强度的生物标志物尚需进一步研究验证。
适用人群与场景
- EDEN试验纳入的急性呼吸窘迫综合征(ARDS)患者,共889例(滋养性肠内营养452例,全量肠内营养437例),使用干预前血浆样本进行二次分析。
- 原文未提及具体的纳入/排除标准、急诊/ICU/院前场景及病情阶段。
诊断标准与关键阈值
- 原文未提及诊断标准、评分界值或启动/停止阈值;仅按GIP三分位分组,最高三分位者显示异质性治疗效应。
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值;仅比较滋养性肠内营养与全量肠内营养两种策略。
- 在最高GIP三分位患者中,滋养性肠内营养较全量肠内营养60天死亡率更低(14.1% vs 27.2%);其他三分位死亡率相似。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:EDEN试验二次分析;样本量889例(滋养性452例,全量437例);人群:ARDS患者;干预:滋养性肠内营养 vs 全量肠内营养;主要终点:60天死亡率。
- GIP预测异质性治疗效应(校正交互p=0.01):最高GIP三分位者滋养性喂养死亡率14.1% vs 全量喂养27.2%,其他三分位死亡率相似。
- GLP-1、ARDS亚表型及基线死亡风险未预测异质性治疗效应。
证据类型、等级与局限
- 证据类型:RCT(EDEN试验)的二次分析;原文未给出证据等级或推荐强度。
- 局限:二次分析,GIP作为生物标志物需进一步研究验证;原文未提及其他局限。
对床旁实践的改变
- 在ARDS患者中,GIP检测(若可及)可能帮助识别从滋养性肠内营养获益更多的亚组(最高GIP三分位者),但原文强调需进一步验证,不能据此常规改变实践。
- GLP-1、ARDS亚表型及基线死亡风险未显示预测价值,不支持用这些指标指导肠内营养强度选择。
指南或共识出处
- EDEN试验(Early versus Delayed Enteral Nutrition)二次分析,发表于Am J Respir Crit Care Med;原文未提及指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: The Early versus Delayed Enteral Nutrition (EDEN) trial found no significant difference in mortality between trophic and full enteral nutrition strategies in acute respiratory distress syndrome (ARDS) patients. Heterogeneity of treatment effect (HTE) has been identified in prior ARDS trials. We previously identified intestine-derived incretin hormones (glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide [GLP]-1 as potential predictive biomarkers in the response to nutrition.
OBJECTIVES: To investigate incretins as biomarkers predictive of HTE in EDEN.
METHODS: GIP, GLP-1, and host immune response biomarkers were measured from pre-intervention EDEN plasma samples. We investigated HTE with 60-day mortality as a primary outcome by testing interaction of treatment with circulating incretin levels in analyses adjusted for demographics, severity of illness, diabetes mellitus, and circulating interleukin-6, and assessed mortality by treatment arm across incretin tertiles. We additionally tested for HTE by de novo ARDS subphenotypes and by risk of mortality.
MEASUREMENTS & MAIN RESULTS: 889 participants were included (452 randomized to trophic and 437 to full enteral nutrition). GIP predicted HTE to enteral nutrition strategies (adjusted interaction p-value 0.01) with lower mortality from trophic feeds (14.1% vs 27.2% in full) in patients in the highest GIP tertile but similar mortality in other tertiles. GLP-1, ARDS subphenotypes, and baseline risk of mortality did not predict HTE.
CONCLUSIONS: GIP was unique among incretins in predicting HTE to enteral nutrition strategies in EDEN. Further studies are needed to validate our findings as GIP might serve as a biomarker to guide level of enteral nutrition for ARDS patients.
参考来源
- Hansell CE, Aneis HA, Yang Z, et al. Incretins Predict Response to Enteral Nutrition Strategies in the EDEN Trial: A Secondary Analysis. Am J Respir Crit Care Med. 2026. PMID: 42439515. doi:10.1093/ajrccm/aamag366
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。